Skip to main content
Chimin Health Management Co., Ltd. logo

Chimin Health Management Co., Ltd. — Investor Relations & Filings

Ticker · 603222 ISIN · CNE100002193 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,324 across all filing types
Latest filing 2026-05-27 Call Transcript
Country CN China
Listing Shanghai Stock Exchange 603222

About Chimin Health Management Co., Ltd.

https://www.chimin.cn/en/

Chimin Health Management Co., Ltd. specializes in the research, development, manufacturing, and distribution of medical devices and pharmaceutical products. The company's core portfolio includes non-PVC soft bag large volume injections, safety syringes, sterile syringes, and blood collection needles. It focuses on providing comprehensive solutions for infusion therapy and blood purification. Chimin Health Management emphasizes the integration of medical technology with health management services, aiming to improve patient safety through innovative designs like auto-disable and safety-engineered medical consumables. The company operates multiple production bases and maintains a strong focus on quality control and technological advancement in the medical supplies sector.

Recent filings

Filing Released Lang Actions
济民健康管理股份有限公司关于2025年年度暨2026年第一季度业绩说明会召开情况的公告
Call Transcript Classification · 72% confidence The document is an announcement and summary of a ‘业绩说明会’ (performance explanation meeting) held to discuss the 2025 annual and 2026 Q1 results, including Q&A with investors. It is not the full annual or interim report itself, nor merely a publication notice. Rather, it provides the substance of an earnings briefing and investor Q&A session, matching the description of a conference call/transcript. Therefore, it should be classified as a Call Transcript (CT).
2026-05-27 Chinese
济民健康管理股份有限公司关于控股子公司取得专利权转让手续合格通知书的公告
Regulatory Filings Classification · 75% confidence The document is a short corporate announcement (“公告”) by a listed company describing its subsidiary’s completion of patent transfer formalities and regulatory approval. It does not contain financial statements, management discussion, or meeting materials; it is not a capital/financing update or M&A filing. It is a general compliance/regulatory announcement about intellectual property rights. Therefore it best fits the fallback category “Regulatory Filings” (RNS).
2026-05-25 Chinese
上海市锦天城律师事务所关于济民健康管理股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 82% confidence The document is a legal opinion letter issued by a law firm regarding the convening procedures, attendee qualifications, voting process, and results of the company’s 2025 annual general meeting. It functions as an attestation/certification rather than the actual AGM materials or a standalone voting‐results announcement. Under the certification rule, such compliance/legal opinion letters are classified as Regulatory Filings (RNS), not as the underlying report or DVA, since it is essentially a lawyer’s attestation.
2026-05-21 Chinese
济民健康管理股份有限公司2025年年度股东会会议资料
AGM Information Classification · 90% confidence The document is the complete set of materials for the company’s 2025 Annual General Meeting (agenda, meeting instructions, board work report, proposals for profit distribution, auditor renewal, director compensation, credit facilities, guarantees, independent directors’ report, and voting forms). It is not a standalone annual or quarterly report, nor an earnings release or regulatory notice, but rather the packet of presentations and materials provided at the AGM. Therefore, it should be classified as AGM Information (AGM-R).
2026-05-13 Chinese
济民健康管理股份有限公司关于公司控股股东协议转让股份终止的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement regarding the termination of a previously planned agreement for the transfer of shares by the company's controlling shareholder. It details the background of the agreement, the termination of the agreement, and the impact on the company. There is no financial data, no report attached or referenced as being published, and no mention of a meeting or voting results. The document is a regulatory announcement about a capital transaction that did not proceed, specifically about a share transfer agreement termination. This fits best under the category of Capital/Financing Update (CAP), as it concerns changes in share ownership agreements and capital structure activities, even though the transaction was terminated. The document length is short and it is not a report publication announcement or a regulatory filing fallback. Therefore, the classification is CAP with high confidence.
2026-05-08 Chinese
济民健康管理股份有限公司2026年第一次临时股东会会议材料
AGM Information Classification · 95% confidence The document is titled as materials for the "2026 First Extraordinary General Meeting (EGM)" of 济民健康管理股份有限公司. It contains detailed agenda items, voting procedures, and proposals to be discussed and voted on at the meeting, including a capital increase involving a subsidiary, a three-year shareholder return plan, and amendments to the remuneration system for directors and senior management. The content is clearly preparatory and informational material for the shareholders to review before or during the EGM. It does not contain actual financial statements or results, nor is it a transcript or announcement of voting results. It is not an annual or interim report, nor a regulatory filing or legal proceeding update. The document fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during general meetings (including extraordinary meetings). Therefore, the correct classification is AGM Information (AGM-R). The document length (8866 characters) supports it being a full meeting material rather than a brief announcement.
2026-03-26 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.